Evaluating the survival benefit of kidney retransplantation

被引:122
作者
Rao, Panduranga S.
Schaubel, Douglas E.
Wei, Guanghui
Fenton, Stanley S. A.
机构
[1] Univ Michigan, Dept Internal Med, Div Nephrol, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Sch Publ Hlth, Dept Biostat, Ann Arbor, MI 48109 USA
[3] Univ Toronto, Toronto Gen Hosp, Div Nephrol, Toronto, ON M5G 1L7, Canada
关键词
graft failure; retransplantation; survival benefit;
D O I
10.1097/01.tp.0000235434.13327.11
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 [免疫学];
摘要
Background. The magnitude of the survival benefit associated with kidney retransplantation has not been well studied. Methods. Using data from the Canadian Organ Replacement Register (CORR), we studied patients (n = 3,067) initiating renal replacement therapy during 1981-1998 who had received a transplant and experienced graft failure (GF). Such patients were followed until death, loss to follow-up or the end of the observation period (December 31, 1998). Using Cox regression, we estimated the post-GF covariate-adjusted hazard ratio (HR) for retransplant versus dialysis, and determined whether the contrast differed across patient subgroups. Through nonproportional hazards models, we also examine patterns in the retransplant/dialysis HR with time following retransplant. Results. Overall, retransplantation is associated with a covariate-adjusted 50% reduction in mortality, relative to remaining on dialysis (HR=0.50; P < 0.0001). This benefit is most pronounced in the 18- to 59-year age group. Retransplanted patients were at significantly higher risk of death relative to patients on dialysis only during the first month posttransplant (HR = 1.66; P = 0.047), and experienced significantly reduced mortality thereafter. Conclusions. Following primary graft failure, retransplantation is associated with significantly reduced mortality rates among Canadian end-stage renal disease patients. Further study should be undertaken to assess the applicability of our findings to other patient populations.
引用
收藏
页码:669 / 674
页数:6
相关论文
共 23 条
[1]
RISK-FACTORS FOR 2ND RENAL-ALLOGRAFTS IMMUNOSUPPRESSED WITH CYCLOSPORINE [J].
ALMOND, PS ;
MATAS, AJ ;
GILLINGHAM, K ;
TROPPMANN, C ;
PAYNE, W ;
DUNN, D ;
SUTHERLAND, D ;
NAJARIAN, JS .
TRANSPLANTATION, 1991, 52 (02) :253-258
[2]
100 2ND RENAL-ALLOGRAFTS FROM A SINGLE TRANSPLANTATION INSTITUTION [J].
ASCHER, NL ;
AHRENHOLZ, DH ;
SIMMONS, RL ;
NAJARIAN, JS .
TRANSPLANTATION, 1979, 27 (01) :30-34
[3]
Living-donor kidney retransplantation: risk factors and outcome [J].
El-Agroudy, AE ;
Wafa, EW ;
Bakr, MA ;
Donia, AF ;
Ismail, AM ;
Shokeir, AA ;
Shehab El-Dein, AB ;
Ghoneim, MA .
BJU INTERNATIONAL, 2004, 94 (03) :369-373
[4]
RENAL RETRANSPLANTATION - THE ROLE OF RACE QUADRUPLE IMMUNOSUPPRESSION, AND THE FLOW-CYTOMETRY CROSS-MATCH [J].
GASTON, RS ;
SHROYER, TW ;
HUDSON, SL ;
DEIERHOI, MH ;
LASKOW, DA ;
BARBER, WH ;
JULIAN, BA ;
CURTIS, JJ ;
BARGER, BO ;
DIETHELM, AG .
TRANSPLANTATION, 1994, 57 (01) :47-54
[5]
Mortality after kidney transplant failure: The impact of non-immunologic factors [J].
Gill, JS ;
Abichandani, R ;
Kausz, AT ;
Pereira, BJG .
KIDNEY INTERNATIONAL, 2002, 62 (05) :1875-1883
[6]
Improved graft survival after renal transplantation in the United States, 1988 to 1996. [J].
Hariharan, S ;
Johnson, CP ;
Bresnahan, BA ;
Taranto, SE ;
McIntosh, MJ ;
Stablein, D .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (09) :605-612
[7]
*HHS HRSA HSB DOT, 2004, OPTN SRTR ANN REP 19
[8]
HOWARD RJ, 1984, ARCH SURG-CHICAGO, V119, P796
[9]
What happens to renal transplant recipients who lose their grafts? [J].
Howard, RJ ;
Reed, AI ;
Van der Werf, WJ ;
Hemming, AW ;
Patton, PR ;
Scornik, JC .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2001, 38 (01) :31-35
[10]
Imagawa D K, 1988, Clin Transpl, P387